Immunotherapy in Early-Stage NSCLC

Immunotherapy in Early-Stage NSCLC

Dr Borghaei and Dr Chaft join to discuss recent clinical data supporting the use of immunotherapy in early-stage NSCLC.

 

The goal of this activity is to provide insight on the rationale and clinical trial data for immunotherapy in the treatment of patients with early-stage non-small cell lung cancer (NSCLC).

 

This activity is intended for oncologists, pulmonologists, and pathologists.

 

 

 

Learning Objectives:

  • Have increased knowledge regarding the
    • Rationale for using immunotherapy in early-stage NSCLC
    • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
  • Demonstrate greater confidence in their ability to
    • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

Approximate Time to Complete: 30 minutes

 

Credit Available: February 25, 2022 - February 25, 2023

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

 

Additional Resources for Clinicans from SITC:

 

 

Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the rationale for using immunotherapy in early-stage NSCLC.
  • Demonstrate greater confidence in their understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC.
  • Have increased knowledge regarding the Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC.
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.25
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.25